Roche: favourable data for bladder cancer drug
(CercleFinance.com) - Roche announces that the Phase III IMvigor130 study for Tecentriq in previously untreated locally advanced cancer of the bladder has met its co-primary endpoint of investigator-assessed progression-free survival.
The combination of this drug plus platinum-based chemotherapy showed a statistically significant reduction in the risk of disease worsening or death (PFS) compared with chemotherapy alone.
"Encouraging overall survival results were observed at this interim analysis; however, these data are not yet mature and follow-up will continue until the next planned analysis," Roche added.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The combination of this drug plus platinum-based chemotherapy showed a statistically significant reduction in the risk of disease worsening or death (PFS) compared with chemotherapy alone.
"Encouraging overall survival results were observed at this interim analysis; however, these data are not yet mature and follow-up will continue until the next planned analysis," Roche added.
Copyright (c) 2019 CercleFinance.com. All rights reserved.